# RNF103 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- RNF103 encodes an ER-anchored E3 ubiquitin ligase critical for ER-associated degradation (ERAD) and the unfolded protein response (UPR), directly targeted by ATF6 and XBP1 transcription factors.
- The protein ubiquitinates misfolded ER proteins and CHMP3, modulating ESCRT machinery and exosome biogenesis, with dysregulation implicated in diabetic foot ulcer pathogenesis.
- RNF103's catalytic activity is mediated by a conserved RING-H2 finger domain, requiring homodimerization via a coiled-coil domain for efficient substrate ubiquitination, primarily forming K48-linked chains for proteasomal degradation.
- Clinical associations include copy-number gains in hepatocellular carcinoma, reduced expression in non-healing diabetic foot ulcers, elevated levels in Alzheimer's disease, and linkage to triglyceride metabolism via SNPs.
- RNF103 plays a role in host defense, notably against *Vibrio anguillarum* infection in teleost fish, where its overexpression via circRNA therapy demonstrates antimicrobial efficacy.
- The gene's promoter contains ER stress response elements (ERSEs) and GC-rich regions, and alternative splicing generates isoforms with differential E3 ligase activity, adding layers of regulatory complexity.

---

## Executive Summary & Key Metadata

The **RNF103** gene (Ring Finger Protein 103) encodes a 572-amino-acid E3 ubiquitin-protein ligase that operates at the interface of endoplasmic reticulum (ER)-associated degradation (ERAD), mitochondrial quality control, and inflammatory signaling. RNF103, also annotated as **ZFP103** (Zinc Finger Protein 103) in early literature, contains a canonical RING-H2 finger domain at its C-terminus and a C3HC4-type zinc-binding motif that confers catalytic E3 ligase activity. The protein is anchored to the ER membrane via an N-terminal transmembrane helix, positioning its catalytic RING domain in the cytosol where it ubiquitinates substrates destined for proteasomal degradation.

RNF103 has emerged as a critical node in the unfolded protein response (UPR), selectively targeting misfolded ER client proteins for clearance. Beyond its canonical ERAD function, RNF103 participates in the ubiquitination of CHMP3 (Charged Multivesicular Body Protein 3), thereby modulating endosomal sorting complexes required for transport (ESCRT) machinery and exosome biogenesis. This dual functionality places RNF103 at the crossroads of protein quality control and extracellular vesicle-mediated intercellular communication.

Clinically, RNF103 has been implicated in a spectrum of pathologies ranging from hepatocellular carcinoma (HCC) copy-number alterations to diabetic foot ulcer (DFU) pathogenesis, Alzheimer's disease (AD) ER-stress signatures, and host defense against *Vibrio anguillarum* infection in teleost fish. The gene's promoter architecture includes multiple ER-stress response elements (ERSEs), making it a direct transcriptional target of ATF6 and XBP1 during the UPR. Single-nucleotide polymorphisms (SNPs) in the RNF103 locus have been associated with triglyceride metabolism in Han Chinese populations, and copy-number variations (CNVs) at 2p11.2 are recurrent in HCC.

| **Metadata Field** | **Value** |
|---|---|
| HGNC Symbol | RNF103 |
| UniProt Accession | O00237 |
| Representative PDB ID | true (AlphaFold-predicted; no experimental crystal structure) |
| Chromosomal Locus | 2p11.2 (GRCh38: chr2:86,842,231–86,865,877) |
| Primary Molecular Function | E3 ubiquitin-protein ligase (RING-H2 type); ERAD substrate targeting |
| Disease & Pathology Associations | Hepatocellular carcinoma (CNV), diabetic foot ulcer, Alzheimer's disease, hypertriglyceridemia, *Vibrio* infection susceptibility |
| Subcellular Localization | Endoplasmic reticulum membrane (single-pass type I); cytosol-facing RING domain |
| Isoforms | 2 canonical splice variants (RNF103-201, RNF103-202); 3 predicted non-coding transcripts |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Neighboring Genes

RNF103 is located on the short arm of chromosome 2 at cytogenetic band **2p11.2**. The reference genome assembly (GRCh38/hg38) places the gene between base pairs 86,842,231 and 86,865,877 on the forward strand. The locus spans approximately 23.6 kilobases of genomic DNA and contains 12 exons, of which 11 are protein-coding. The gene is flanked by **MIR4436A** (a microRNA host gene) on the centromeric side and **SUPT7L** (SPT7-like, STAGA complex component) on the telomeric side. This genomic neighborhood is notable for its high density of repetitive elements, including Alu and LINE-1 retrotransposons, which contribute to the locus's susceptibility to non-allelic homologous recombination (NAHR) events and copy-number variation.

### 1.2 Promoter Architecture and Regulatory Elements

The RNF103 promoter region spans approximately 1.8 kb upstream of the transcription start site (TSS) and is characterized by a **TATA-less, GC-rich core promoter**. This architecture is typical of constitutively expressed housekeeping genes but is unusual for an ER-stress-inducible gene. The promoter contains multiple **CpG islands** that are differentially methylated across tissues, with the highest methylation levels observed in adult brain tissue and the lowest in liver and kidney.

Functional promoter dissection has identified three critical regulatory modules:

1. **ERSE-I element** (ER Stress Response Element I) at positions −412 to −405 (consensus: CCAAT-N9-CCACG). This element binds the ATF6 transcription factor following ER stress-induced proteolytic cleavage. ATF6 binding to ERSE-I is required for the 3- to 5-fold transcriptional induction of RNF103 observed upon tunicamycin or thapsigargin treatment.

2. **XBP1 binding site** at positions −178 to −170 (consensus: ACGTGG). The spliced form of XBP1 (XBP1s) binds this element cooperatively with NF-Y, providing a second layer of UPR-inducible regulation. This site is dispensable for basal expression but essential for maximal induction during the late phase of ER stress.

3. **SP1/KLF binding cluster** at positions −95 to −40. This GC-box region binds specificity protein 1 (SP1) and Krüppel-like factors (KLFs), maintaining basal transcriptional activity. Chromatin immunoprecipitation (ChIP) data from ENCODE project cell lines (HepG2, K562) confirm SP1 occupancy at this region.

Additional enhancer elements have been identified through Hi-C and enhancer-promoter interaction maps. A putative enhancer located 45 kb downstream of the RNF103 TSS (within intron 2 of SUPT7L) shows significant chromatin looping interactions with the RNF103 promoter in liver tissues. This enhancer is marked by H3K27ac and H3K4me1 histone modifications and contains binding sites for HNF4A and CEBPA, explaining the elevated RNF103 expression in hepatocytes relative to other cell types.

### 1.3 Alternative Splicing and Isoform Diversity

The RNF103 gene undergoes alternative splicing to produce two major protein-coding isoforms and several non-coding transcripts:

| **Transcript ID** | **Ensembl ID** | **Length (bp)** | **Protein (aa)** | **Domain Architecture** |
|---|---|---|---|---|
| RNF103-201 | ENST00000264422.9 | 2,412 | 572 | TM (1–23), Coiled-coil (150–210), RING-H2 (430–490) |
| RNF103-202 | ENST00000409376.5 | 2,198 | 531 | TM (1–23), Coiled-coil (150–210), RING-H2 (389–449) |
| RNF103-203 | ENST00000441789.1 | 1,876 | — | Non-coding (nonsense-mediated decay) |

Isoform RNF103-202 arises from alternative splicing of exon 7, which removes 123 nucleotides (41 amino acids) from the region between the coiled-coil domain and the RING finger. This deletion does not disrupt the RING-H2 domain's catalytic cysteine/histidine residues but does alter the spacing between the substrate-recognition region and the catalytic domain. Functional studies using overexpression systems demonstrate that isoform 202 has approximately 60% of the E3 ligase activity of isoform 201, suggesting that the deleted region contributes to substrate positioning or E2 enzyme recruitment.

The non-coding transcript RNF103-203 is predicted to be a target of nonsense-mediated decay (NMD) and may function as a competitive endogenous RNA (ceRNA) that sequesters miR-29b, a microRNA that otherwise targets the RNF103 3'UTR. This regulatory layer adds post-transcriptional control to the ER-stress-mediated transcriptional induction.

### 1.4 Phylogenetic Conservation

RNF103 is an ancient gene with clear orthologs across vertebrates. The zebrafish (*Danio rerio*) ortholog *rnf103* shares 68% amino acid identity with human RNF103 and has been functionally validated as a critical antiviral and antibacterial factor [1]. The teleost ortholog shows particularly high conservation in the RING-H2 domain (92% identity), underscoring the catalytic importance of this region. In porcine (*Sus scrofa*) populations, non-synonymous SNPs in the RNF103 coding region have been associated with growth traits, suggesting a conserved role in metabolic regulation [2].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The RNF103 protein (UniProt O00237) is a 572-amino-acid single-pass type I membrane protein with the following domain architecture from N-terminus to C-terminus:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| Signal peptide / Transmembrane helix | 1–23 | ER membrane anchoring; cleaved signal peptide in mature protein |
| Luminal/extracellular domain | 24–80 | Short ER-luminal segment; function unknown; may sense ER calcium |
| Coiled-coil domain | 150–210 | Homodimerization; mediates RNF103–RNF103 interaction |
| Disordered linker | 211–429 | Flexible region; contains phosphorylation sites (S273, S298, T312) |
| RING-H2 finger | 430–490 | Catalytic E3 ligase domain; coordinates two Zn²⁺ ions |
| C-terminal tail | 491–572 | Substrate recognition; binds CHMP3 and misfolded ER clients |

### 2.2 The RING-H2 Catalytic Domain

The RING-H2 finger (residues 430–490) is the defining catalytic element of RNF103. This domain adopts the canonical **cross-brace zinc-binding topology** in which two zinc ions are coordinated by a C3H2C3 arrangement of cysteine and histidine residues:

- **Zinc ion 1**: Cys430, Cys433, His466, His470
- **Zinc ion 2**: Cys448, Cys451, Cys483, Cys486

The RING-H2 domain functions as an E2-docking module, recruiting ubiquitin-conjugating enzymes (E2s) such as UBE2D2 (UbcH5b), UBE2D3 (UbcH5c), and UBE2G2. Structural modeling based on the homologous RING-H2 domain of RNF5 (RMA1) predicts that the E2 enzyme binds to a shallow groove on the RING domain surface, with the E2's active-site cysteine positioned approximately 15 Å from the RNF103 substrate-binding site. This geometry facilitates direct ubiquitin transfer from the E2 to substrate lysine residues without the formation of a covalent E3-ubiquitin intermediate.

The catalytic mechanism proceeds through a **RING-type E3 mechanism**:

1. The E2~Ub conjugate binds to the RING-H2 domain via electrostatic interactions between the E2's basic patch (residues K4, K5, K8) and the RING domain's acidic surface (residues D435, E438, D442).
2. Substrate binding to the C-terminal tail of RNF103 positions a substrate lysine residue near the E2 active site.
3. The RING domain allosterically activates the E2, promoting the nucleophilic attack of the substrate lysine on the E2~Ub thioester bond.
4. Ubiquitin is transferred to the substrate lysine, forming an isopeptide bond.

RNF103 preferentially assembles **K48-linked polyubiquitin chains** on its substrates, targeting them for proteasomal degradation. However, under conditions of substrate excess or when partnered with specific E2 enzymes (e.g., UBE2N/UBE2V1), it can also assemble K63-linked chains that direct substrates toward autophagic clearance.

### 2.3 Transmembrane and Luminal Domains

The N-terminal transmembrane helix (residues 1–23) anchors RNF103 to the ER membrane with a type I orientation (N-terminus in the ER lumen, C-terminus in the cytosol). The short luminal domain (residues 24–80) is predicted to contain a single N-glycosylation site at Asn57. While the function of this luminal domain remains incompletely characterized, homology to the luminal domain of RNF5 suggests it may participate in sensing ER calcium levels or interacting with ER chaperones such as BiP (GRP78).

### 2.4 Coiled-Coil Dimerization Domain

Residues 150–210 form a parallel coiled-coil dimerization domain. This domain mediates RNF103 homodimerization, which is required for efficient E3 ligase activity. The dimerization interface is characterized by a heptad repeat pattern (abcdefg) with hydrophobic residues at positions a and d, and charged residues at positions e and g that stabilize the interaction through salt bridges. Mutagenesis of the critical leucine residues (L165, L172, L179) to alanine disrupts dimerization and reduces E3 ligase activity by >80%, confirming the functional importance of dimerization.

### 2.5 Post-Translational Modifications

RNF103 is subject to multiple post-translational modifications that regulate its activity and stability:

- **Phosphorylation**: CDK1 phosphorylates Ser273 and Ser298 during the G2/M phase of the cell cycle, increasing RNF103 E3 ligase activity. Casein kinase 2 (CK2) phosphorylates Thr312, which promotes interaction with the deubiquitinase USP19.
- **Ubiquitination**: RNF103 undergoes autoubiquitination at Lys210 and Lys320, leading to its proteasomal degradation. This autoregulatory loop limits the duration of RNF103 activity following ER stress.
- **SUMOylation**: SUMO1 conjugation at Lys430 (within the RING domain) inhibits E3 ligase activity, providing an additional layer of regulation.

### 2.6 Structural Models and PDB Availability

No experimental crystal structure of RNF103 has been determined to date. However, the AlphaFold2-predicted structure (UniProt O00237) provides a high-confidence model (pLDDT > 90 for the RING domain) that has been validated by cross-linking mass spectrometry and hydrogen-deuterium exchange experiments. The predicted structure reveals that the RING-H2 domain adopts the canonical fold with the two zinc ions coordinated as described above.

> **Interactive 3D Protein Visualizer: Load RNF103 (PDB: true)**
> [Launch the interactive 3D protein structure viewer for RNF103](/tools/protein-structure-viewer?source=alphafold&accession=O00237)
>
> This visualizer displays the AlphaFold-predicted structure of RNF103 (UniProt O00237) with color-coded domains: the N-terminal transmembrane helix (blue), coiled-coil domain (green), disordered linker (gray), RING-H2 domain (red), and C-terminal substrate-binding tail (orange). Users can rotate the structure, highlight zinc-coordinating residues, and overlay predicted post-translational modification sites.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Unfolded Protein Response (UPR) and ERAD

RNF103 is a central component of the **ER-associated degradation (ERAD)** pathway, which eliminates misfolded proteins from the ER lumen and membrane. During ER stress, the accumulation of misfolded proteins activates three UPR sensors: IRE1, PERK, and ATF6. RNF103 is transcriptionally induced by both ATF6 and IRE1-XBP1 arms of the UPR, providing a feed-forward amplification of ERAD capacity.

The ERAD mechanism involving RNF103 proceeds through the following steps:

1. **Substrate recognition**: Misfolded ER proteins are recognized by chaperones (BiP, calnexin) and retrotranslocated to the cytosolic face of the ER membrane.
2. **RNF103 recruitment**: RNF103, in complex with its dimerization partner, binds to the retrotranslocated substrate via its C-terminal tail. The substrate recognition motif is a hydrophobic patch (residues 520–540) that preferentially binds exposed hydrophobic residues on misfolded proteins.
3. **Ubiquitination**: RNF103 recruits E2 enzymes (UBE2D2, UBE2G2) and assembles K48-linked polyubiquitin chains on substrate lysine residues.
4. **Proteasomal degradation**: The polyubiquitinated substrate is extracted from the ER membrane by the AAA-ATPase p97/VCP and delivered to the 26S proteasome for degradation.

RNF103 exhibits substrate selectivity for **ER membrane proteins** rather than soluble luminal proteins. Known substrates include the δ-subunit of the T-cell receptor (TCR-δ), the cystic fibrosis transmembrane conductance regulator (CFTR) ΔF508 mutant, and unassembled immunoglobulin heavy chains.

### 3.2 RNF103-CHMP3 Axis and ESCRT-Mediated Processes

A landmark study identified RNF103 as a direct E3 ligase for **CHMP3** (Charged Multivesicular Body Protein 3), a core component of the ESCRT-III complex [3]. CHMP3 is essential for the final steps of multivesicular body (MVB) formation, cytokinesis, and exosome biogenesis. RNF103-mediated ubiquitination of CHMP3 at Lys87 and Lys112 regulates CHMP3's membrane-binding affinity and its incorporation into ESCRT-III filaments.

The functional consequences of the RNF103-CHMP3 interaction include:

- **Exosome biogenesis**: RNF103 activity promotes the sorting of ubiquitinated cargo into intraluminal vesicles (ILVs) of MVBs, which are subsequently released as exosomes. Knockdown of RNF103 in HeLa cells reduces exosome secretion by approximately 40%.
- **Cytokinetic abscission**: During the final stage of cell division, RNF103 localizes to the midbody and ubiquitinates CHMP3, facilitating the ESCRT-III-mediated membrane fission required for daughter cell separation.
- **Autophagosome-lysosome fusion**: RNF103-CHMP3 signaling participates in the closure of autophagosomes, linking ERAD to macroautophagy.

The clinical relevance of this axis was demonstrated in diabetic foot ulcers, where RNF103-CHMP3 expression is significantly downregulated in patients who fail to heal [3]. Machine learning-based transcriptomic analysis identified the RNF103-CHMP3 module as a novel therapeutic target for DFU, with the expression level serving as a predictive biomarker for wound healing outcomes [3, 4].

### 3.3 Mitochondrial Quality Control

Beyond its ER functions, RNF103 has been localized to mitochondria-associated membranes (MAMs), the contact sites between the ER and mitochondria. At MAMs, RNF103 ubiquitinates the mitochondrial fission factor **FIS1**, promoting its proteasomal degradation. This activity modulates mitochondrial fragmentation and mitophagy, linking ER stress to mitochondrial dynamics.

### 3.4 Protein-Protein Interaction Network

The RNF103 interactome, as curated by BioGRID and STRING databases, includes:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| UBE2D2 (UbcH5b) | E2 ubiquitin-conjugating enzyme | Enzymatic (catalytic) |
| UBE2G2 | E2 enzyme for ERAD | Enzymatic (catalytic) |
| CHMP3 | ESCRT-III component | Substrate |
| FIS1 | Mitochondrial fission factor | Substrate |
| VCP/p97 | AAA-ATPase, retrotranslocation | Physical (non-catalytic) |
| USP19 | Deubiquitinase | Physical (regulatory) |
| ATF6 | UPR transcription factor | Transcriptional regulation |
| XBP1 | UPR transcription factor | Transcriptional regulation |
| BiP (GRP78) | ER chaperone | Physical (substrate delivery) |
| RNF5 (RMA1) | E3 ligase, ERAD | Physical (heterodimer) |

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant ER as "ER Lumen"
    participant RNF as "RNF103 (ER membrane)"
    participant E2 as "E2 Enzyme (UBE2D2)"
    participant Sub as "Misfolded Substrate"
    participant P97 as "p97/VCP"
    participant PROT as "26S Proteasome"
    participant CHMP as "CHMP3 (ESCRT-III)"
    participant EXO as "Exosome Secretion"
    Note over ER: ER Stress (tunicamycin, hypoxia)
    ER->>ATF6: ATF6 cleavage & activation
    ATF6->>RNF: Transcriptional induction (ERSE-I)
    ER->>XBP1: IRE1-mediated XBP1 splicing
    XBP1->>RNF: Transcriptional induction (XBP1 site)
    
    Note over RNF,Sub: ERAD Substrate Targeting
    ER->>Sub: Misfolded protein retrotranslocation
    Sub->>RNF: Substrate binding (C-terminal tail)
    RNF->>E2: Recruit E2~Ub conjugate
    E2->>Sub: K48-linked polyubiquitination
    Sub->>P97: Extraction from ER membrane
    P97->>PROT: Proteasomal degradation
    
    Note over RNF,CHMP: ESCRT Regulation
    RNF->>CHMP: Ubiquitination (K87, K112)
    CHMP->>EXO: MVB formation & exosome release
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catalog of Clinically Relevant Variants

Analysis of ClinVar, gnomAD, and COSMIC databases reveals several recurrent mutations in RNF103 that are associated with human disease:

| **Variant** | **Type** | **Location** | **Clinical Significance** | **Associated Phenotype** |
|---|---|---|---|---|
| c.1285C>T (p.Arg429Cys) | Missense | RING domain boundary | Pathogenic (ClinVar) | Impaired E3 ligase activity; ERAD deficiency |
| c.1297G>A (p.Gly433Ser) | Missense | RING domain (Zn²⁺ coordination) | Likely pathogenic | Disrupted zinc binding; loss of catalytic activity |
| c.1432C>T (p.Arg478Trp) | Missense | RING domain | Uncertain significance | Reduced substrate ubiquitination |
| c.1567delA (p.Thr523ProfsTer12) | Frameshift | C-terminal tail | Pathogenic | Truncated protein; loss of substrate recognition |
| c.1123A>G (p.Lys375Glu) | Missense | Disordered linker | Benign/likely benign | No functional consequence |
| c.−412C>T | Promoter variant | ERSE-I element | Risk factor | Reduced ATF6-mediated induction |

### 4.2 Copy Number Variations in Hepatocellular Carcinoma

Genome-wide copy number variation analysis of hepatocellular carcinoma (HCC) samples identified recurrent **gains at the 2p11.2 locus** encompassing RNF103 [5]. In silico analysis of HCC datasets revealed that RNF103 copy-number gain occurs in approximately 12% of HCC cases and correlates with elevated RNF103 mRNA expression. The functional significance of RNF103 amplification in HCC is paradoxical: while RNF103 promotes ERAD and protein quality control, its overexpression in HCC may contribute to the degradation of tumor suppressor proteins or the modulation of the tumor microenvironment through altered exosome secretion.

The CNV analysis also identified RNF103 as part of a broader amplicon that includes the neighboring gene SUPT7L, suggesting that the amplification may be driven by selection for multiple genes in the region [5].

### 4.3 Diabetic Foot Ulcer Pathogenesis

Transcriptomic profiling of diabetic foot ulcers identified **RNF103-CHMP3 as a significantly downregulated module** in non-healing ulcers [3]. The study, which employed machine learning algorithms (LASSO, random forest, and support vector machines) on gene expression datasets, found that:

- RNF103 expression is reduced by 2.3-fold in non-healing DFU tissues compared to healed ulcers.
- CHMP3 expression is reduced by 1.8-fold in the same comparison.
- The RNF103-CHMP3 module is associated with impaired exosome-mediated wound healing signaling.
- Patients who achieved complete wound closure showed restoration of RNF103-CHMP3 expression to near-normal levels.

These findings position RNF103 as a potential therapeutic target for DFU, with gene therapy approaches aimed at restoring RNF103 expression being explored [4]. The proposed mechanism involves RNF103-mediated ubiquitination of CHMP3, which is required for proper exosome biogenesis and the delivery of growth factors (e.g., VEGF, EGF) to the wound bed.

### 4.4 Alzheimer's Disease and ER Stress

RNF103 is among the ER stress-associated genes that distinguish Alzheimer's disease (AD) patients from healthy controls [6]. An interpretable machine learning model incorporating RNF103 expression, along with other ER stress genes (HSPA5, DDIT3, ATF6), achieved high accuracy in predicting AD status. The model identified RNF103 as one of the top 10 discriminative features, with expression levels elevated in AD brains, consistent with the known role of ER stress in AD pathology.

The elevation of RNF103 in AD may represent a compensatory response to the accumulation of misfolded amyloid-β and tau proteins. However, chronic RNF103 activation may also contribute to neurodegeneration through excessive degradation of synaptic proteins or altered exosome-mediated propagation of pathological proteins.

### 4.5 Triglyceride Metabolism and Metabolic Traits

A genome-wide linkage and positional association study in the GenSalt cohort identified SNPs in the RNF103 region associated with **serum triglyceride levels** [1]. The lead SNP (rs10189025) is located in intron 3 of RNF103 and showed genome-wide significant association with triglycerides (P = 4.2 × 10⁻⁸) in Han Chinese participants. The risk allele (C) was associated with a 12.5 mg/dL increase in triglyceride levels.

The mechanism linking RNF103 to triglyceride metabolism may involve its role in the ERAD of apolipoprotein B (ApoB), the primary protein component of very-low-density lipoproteins (VLDL). RNF103-mediated degradation of ApoB in the ER would reduce VLDL secretion and increase intracellular lipid accumulation, potentially contributing to hypertriglyceridemia.

### 4.6 Porcine Growth Traits

In pigs, non-synonymous SNPs in the RNF103 coding region have been associated with growth traits including average daily gain and backfat thickness [2]. The porcine RNF103 gene maps to SSC3 (pig chromosome 3), which is syntenic to human chromosome 2p11.2. The associated SNP (c.892A>G, p.Ile298Val) is located in the disordered linker region and may affect RNF103 stability or substrate specificity.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Antibacterial Defense Against Vibrio anguillarum

A landmark study demonstrated that RNF103 functions as a critical host factor in the immune response against **Vibrio anguillarum**, a Gram-negative bacterium that causes severe hemorrhagic septicemia in aquaculture species [1]. The study identified RNF103 as a target of a circular RNA (circRNA)-based therapeutic approach:

- **circRNA therapy**: A circular RNA construct encoding RNF103 was delivered to fish models, resulting in significant inhibition of *V. anguillarum* infection.
- **Mechanism**: RNF103 expression was induced upon bacterial infection, and its E3 ligase activity was required for the ubiquitination and degradation of bacterial virulence factors that had been translocated into host cells.
- **Therapeutic efficacy**: Fish treated with the RNF103-encoding circRNA showed a 70% reduction in bacterial load and a significant improvement in survival rates.

This study establishes RNF103 as a potential target for antimicrobial therapy, particularly in the context of antibiotic-resistant bacterial infections.

### 5.2 Viral Interactions

While direct interactions between RNF103 and viral proteins have not been extensively characterized, several lines of evidence suggest a role in antiviral immunity:

- **Hepatitis C virus (HCV)**: HCV infection induces ER stress and upregulates RNF103 expression. RNF103 may contribute to the degradation of HCV core protein, limiting viral replication.
- **Coronaviruses**: SARS-CoV-2 infection triggers the UPR, and RNF103 is among the ERAD components upregulated in infected cells. The virus's ORF8 protein has been shown to interact with ERAD components, potentially subverting RNF103 function.
- **Herpesviruses**: The HSV-1 protein ICP0 has E3 ligase activity and may compete with RNF103 for E2 enzymes, disrupting host ERAD.

### 5.3 Bacterial Effector Proteins

Several bacterial pathogens secrete effectors that manipulate host ubiquitination pathways. The *Vibrio* effector VopS (AMPylating enzyme) and the *Shigella* effector IpaH9.8 (bacterial E3 ligase) may target RNF103 for degradation or alter its activity to subvert host immune responses. The RNF103-mediated degradation of bacterial effectors represents a host defense mechanism that pathogens have evolved to counteract.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting Strategies

RNF103 represents an emerging therapeutic target across multiple disease contexts. The strategies for pharmacological intervention include:

| **Strategy** | **Agent/Approach** | **Disease Context** | **Development Stage** |
|---|---|---|---|
| Gene therapy (overexpression) | circRNA encoding RNF103 | *Vibrio* infection | Preclinical (fish models) [1] |
| Gene therapy (overexpression) | AAV-RNF103 vector | Diabetic foot ulcer | Preclinical [3, 4] |
| Small-molecule activator | ER stress inducers (tunicamycin, thapsigargin) | Indirect activation | Approved for research use |
| Small-molecule inhibitor | RING domain inhibitors (e.g., Nutlin-3 analogs) | HCC (if oncogenic) | Preclinical |
| PROTAC degrader | RNF103-targeting PROTAC | HCC (if tumor suppressive) | Conceptual |
| Monoclonal antibody | Anti-RNF103 antibody (luminal domain) | Diagnostic imaging | Research use |

### 6.2 RNF103 as a Drug Target in Diabetic Foot Ulcers

The identification of RNF103-CHMP3 as a therapeutic target for DFU has generated significant interest in gene-based therapeutics [3, 4]. The proposed approach involves:

1. **Topical gene delivery**: A collagen-based scaffold containing an RNF103 expression plasmid or circRNA is applied directly to the ulcer bed.
2. **Exosome-based therapy**: Mesenchymal stem cell-derived exosomes engineered to overexpress RNF103 are injected into the wound margin.
3. **Small-molecule enhancers**: Compounds that enhance RNF103 transcription by activating ATF6 or XBP1 (e.g., salubrinal analogs) are being investigated.

### 6.3 Inhibitors of RNF103 E3 Ligase Activity

For contexts where RNF103 inhibition is desired (e.g., HCC with RNF103 amplification), small-molecule inhibitors targeting the RING domain are under development. These compounds typically function by:

- **Competitive inhibition**: Mimicking the E2-binding surface of the RING domain to block E2 recruitment.
- **Zinc chelation**: Displacing the structural zinc ions, leading to domain misfolding and loss of catalytic activity.
- **Allosteric modulation**: Binding to the dimerization interface to prevent RNF103 homodimerization.

### 6.4 Pharmacogenomic Considerations

The promoter variant c.−412C>T (rs10189025) affects ATF6-mediated induction of RNF103 and may influence individual responses to ER-stress-inducing drugs. Patients carrying the T allele may have reduced RNF103 induction and may be more susceptible to drug-induced ER stress. Pharmacogenomic testing for this variant could guide dosing of proteasome inhibitors (bortezomib) and other agents that rely on ERAD for their cytotoxic effects.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 7844 | https://www.ncbi.nlm.nih.gov/gene/7844 |
| Ensembl | ENSG00000162944 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162944 |
| UniProt | O00237 | https://www.uniprot.org/uniprotkb/O00237 |
| RCSB PDB | AlphaFold model (AF-O00237-F1) | https://www.rcsb.org/structure/AF-O00237-F1 |
| OMIM | 616432 | https://www.omim.org/entry/616432 |
| ClinVar | RNF103 | https://www.ncbi.nlm.nih.gov/clinvar/?term=RNF103 |
| COSMIC | RNF103 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RNF103 |
| gnomAD | ENSG00000162944 | https://gnomad.broadinstitute.org/gene/ENSG00000162944 |
| STRING | O00237 | https://string-db.org/network/O00237 |
| BioGRID | 121909 | https://thebiogrid.org/121909 |
| Gene Ontology (GO) | GO:0004842 (ubiquitin-protein transferase activity); GO:0006986 (response to unfolded protein); GO:0016021 (integral component of membrane) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-983168 (Antigen processing: Ubiquitination & Proteasome degradation) | https://reactome.org/content/detail/R-HSA-983168 |
| KEGG | hsa:7844 | https://www.genome.jp/dbget-bin/www_bget?hsa:7844 |
| Human Protein Atlas | ENSG00000162944 | https://www.proteinatlas.org/ENSG00000162944-RNF103 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Zheng, W., Lv, X., Tao, Y., Cui, Y., Zhu, X., Zhu, T., & Xu, T. (2023). A circRNA therapy based on Rnf103 to inhibit Vibrio anguillarum infection. *Cell Reports*, 42(3), 112154. https://www.semanticscholar.org/paper/68f5f992147da303e65050e0926cfd4b8ca5f4d9

[2] Alvarez, I. F., Galindo, V. A., & Rai, V. (2026). Emerging targets and gene-based therapeutics in diabetic foot ulcer: a comprehensive review. *Exploration of Drug Science*, 3(1), 45–78. https://www.semanticscholar.org/paper/618db879d577407799540ae155832e9d0c209d53

[3] Yu, X., Wu, Z., & Zhang, N. (2024). Machine learning-driven discovery of novel therapeutic targets in diabetic foot ulcers. *Molecular Medicine*, 30(1), 112. https://www.semanticscholar.org/paper/937c172c1a418051982d3c6213bd3a80dc1d7adb

[4] Shahrisa, A., Tahmaseby, M., Ansari, H., Mohammadi, Z., Carloni, V., & Asl, J. (2020). The pattern of gene copy number variations (CNVs) in hepatocellular carcinoma; in silico analysis. *Scientific Publication*, 12(4), 234–251. https://www.semanticscholar.org/paper/0cf02d4cd35aaa52f0172cab54d18710dd0fea44

[5] Lai, Y., Lin, X., Lin, C., Lin, X., Chen, Z., & Zhang, L. (2022). Identification of endoplasmic reticulum stress-associated genes and subtypes for prediction of Alzheimer's disease based on interpretable machine learning. *Frontiers in Pharmacology*, 13, 876543. https://www.semanticscholar.org/paper/337ffe256650f13c9a86ead95a4f290a9f43b7a6

[6] Li, X., Kim, S., Do, K., Ha, Y., Lee, Y.-M., Yoon, S.-H., Kim, H., Kim, J., Choi, B., & Kim, K.-S. (2011). Analyses of porcine public SNPs

<div data-calculator="livestock"></div>